MONTREAL, Dec. 20 /PRNewswire/ - Resonant Medical is presently responding to a complaint filed by Varian Medical Systems and SAS PRAXIM of France at the U.S. International Trade Commission (ITC). The subject of the complaint is an allegation of infringement of a single patent sub-licensed from SAS PRAXIM of France.
“Resonant’s products are based on new and innovative technologies, fundamentally different from existing image guidance products for radiation therapy”, explained Resonant Medical CEO, Fred Francis. “We pay the utmost respect to the intellectual property rights of others. We have painstakingly researched our IP positions, and have taken great care to avoid any infringement.”
“Obviously, Resonant Medical will vigorously defend itself against these allegations. Resonant intends to vindicate its rights to compete fairly and to deliver the best possible image guidance solutions to American cancer care providers”, said Mr. Francis.
Resonant’s proprietary 3D ultrasound image guidance technology, the Restitu(TM) Platform, enables clinicians to target tumors more accurately while safeguarding surrounding healthy tissues. With Restitu, radiation oncologists and medical physicists can now visualize and analyze tumor position, shape and volume during the entire course of patient treatment. The Restitu Platform has received FDA 510k clearance and Health Canada License and is presently being used in cancer clinics and academic centers throughout the United States and Canada.
Under the current ITC Investigation, Resonant’s Restitu Platform remains available for importation and sale in the United States without any restriction. “Resonant will continue to roll out Restitu to North American cancer centers, and will maintain the same level of highly responsive support and service for all of its customers”, added Mr. Francis. Resonant is confident that the ITC will find that there has been no violation of Section 337 of the Tariff Act of 1930 and that its Restitu Platform will continue to enjoy success in the U.S. market with no restrictions to its entry, sale, or use.
Resonant Medical Inc. is a leader in 3D ultrasound image-guided adaptive radiotherapy products which are intended to make an important contribution to the treatment of cancer through radiotherapy in the area of treatment planning, verification and delivery. The company’s core product, the Restitu Platform, is designed to increase the efficacy and reduce the side effects of radiation therapy, resulting in improved quality of life for cancer patients as well as enhanced productivity of cancer centers. Resonant Medical recently secured the largest medical device venture capital financing in Canada. Additional information is available on the company website: www.resonantmedical.com
Forward-looking Statements
This news release contains certain forward-looking statements that reflect the current views and/or expectations of Resonant Medical Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may differ materially from those anticipated.
RESONANT MEDICAL INC.
CONTACT: please contact: Michele Jemus, Chief Financial Officer, ResonantMedical, (514) 985-2442, ext. 270, F.: (514) 985-9662,mjemus@resonantmedical.com
